In situ aromatization and enhanced uptake of estradiol from plasma are two potential mechanisms for maintenance of high concentrations of estradiol found in breast tumors of postmenopausal patients. To test the relative importance of these two mechanisms, a nude mouse model was established by inoculating aromatase (A+) and/or sham (A-) transfected MCF-7 cells into ovariectomized mice. Postmenopausal hormonal status was simulated by providing estradiol Silastic implants which clamped plasma estradiol levels at 5-20 pg/ml. We demonstrated that in situ aromatization rather than the uptake mechanism is the key determinant of tumor estradiol levels and tumor growth rate under conditions reflecting the postmenopausal state. The importance of intratumoral aromatase was also suggested by the findings that long-term estrogen deprivation increases sensitivity to estradiol and enhances aromatase activity in MCF-7 cells. The results of our in vivo and in vitro studies suggest that complete blockade of in situ aromatization in the breast would provide added benefit to postmenopausal breast cancer patients, especially those who relapse from antiestrogen therapy.

This article has been cited by other articles:

				Y. H. Ju, D. R. Doerge, K. A. Woodling, J. A. Hartman, J. Kwak, and W. G. Helferich Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Carcinogenesis, November 1, 2008; 29(11): 2162 - 2168. [Abstract] [Full Text] [PDF]

				R. J. Pietras Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer Oncologist, July 1, 2006; 11(7): 704 - 717. [Abstract] [Full Text] [PDF]

				Y. H. Ju, K. F. Allred, C. D. Allred, and W. G. Helferich Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations Carcinogenesis, June 1, 2006; 27(6): 1292 - 1299. [Abstract] [Full Text] [PDF]

				P. W. Parodi Dairy Product Consumption and the Risk of Breast Cancer J. Am. Coll. Nutr., December 1, 2005; 24(suppl_6): 556S - 568S. [Abstract] [Full Text] [PDF]

				K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532. [Abstract] [Full Text] [PDF]

				R. R. Love, P. R. Hutson, T. C. Havighurst, and J. F. Cleary Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer Clin. Cancer Res., February 15, 2005; 11(4): 1500 - 1503. [Abstract] [Full Text] [PDF]

				W. Yue, J.-P. Wang, Y. Li, W. P. Bocchinfuso, K. S. Korach, P. D. Devanesan, E. Rogan, E. Cavalieri, and R. J. Santen Tamoxifen versus Aromatase Inhibitors for Breast Cancer Prevention Clin. Cancer Res., January 15, 2005; 11(2): 925s - 930s. [Abstract] [Full Text] [PDF]

				J. A. Harvey and V. E. Bovbjerg Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk Radiology, January 1, 2004; 230(1): 29 - 41. [Abstract] [Full Text] [PDF]

				W. Yue, J.-P. Wang, M. Conaway, S. Masamura, Y. Li, and R. J. Santen Activation of the MAPK Pathway Enhances Sensitivity of MCF-7 Breast Cancer Cells to the Mitogenic Effect of Estradiol Endocrinology, September 1, 2002; 143(9): 3221 - 3229. [Abstract] [Full Text] [PDF]

				C. J. Gruber, W. Tschugguel, C. Schneeberger, and J. C. Huber Production and Actions of Estrogens N. Engl. J. Med., January 31, 2002; 346(5): 340 - 352. [Full Text] [PDF]

				R. X.-D. Song, G. Mor, F. Naftolin, R. A. McPherson, J. Song, Z. Zhang, W. Yue, J. Wang, and R. J. Santen Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17{beta}-Estradiol J Natl Cancer Inst, November 21, 2001; 93(22): 1714 - 1723. [Abstract] [Full Text] [PDF]